Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Incivek Telaprevir Hepatitis C, chronic List with clinical criteria and/or conditions Complete
Incivek Telaprevir Hepatitis C, chronic List with criteria/condition Complete
Incivek Telaprevir Hepatitis C, chronic List with criteria/condition Complete
Increlex mecasermin Severe primary insulin-like growth factor-1 deficiency Reimburse with clinical criteria and/or conditions Complete
Incruse Ellipta Umeclidinium Chronic obstructive pulmonary disease List with criteria/condition Complete
Inflectra Infliximab Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis List with criteria/condition Complete
Inflectra (Subsequent Entry Biologic) Infliximab Crohn’s disease and Ulcerative Colitis Reimburse with clinical criteria and/or conditions Complete
Inlyta Axitinib Metastatic Renal Cell Carcinoma Reimburse Complete
Inlyta (RFA) Axitinib Metastatic Renal Cell Carcinoma N/A Complete
Inqovi Decitabine-Cedazuridine Myelodysplastic Syndromes (MDS) Reimburse with clinical criteria and/or conditions Complete